Taysha Gene Therapies, Inc. (TSHA) – What Are Brokerages Saying About This Stock?

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given an average rating of “Buy” by the fifteen research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $12.77.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. Wolfe Research assumed coverage on Taysha Gene Therapies in a report on Thursday, September 17th. They set an “outperform” rating for the company. Citizens Jmp reissued a “market outperform” rating and issued a $11.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, July 2nd. Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, June 30th. Finally, Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently added to or reduced their stakes in the business. Polar Capital Holdings Plc lifted its stake in shares of Taysha Gene Therapies by 49.8% in the 4th quarter. Polar Capital Holdings Plc now owns 7,931,403 shares of the company’s stock valued at $43,623,000 after purchasing an additional 2,637,524 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Taysha Gene Therapies by 534.7% in the second quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company’s stock worth $27,074,000 after purchasing an additional 3,349,244 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Taysha Gene Therapies in the fourth quarter worth $20,471,000. ADAR1 Capital Management LLC increased its position in Taysha Gene Therapies by 19.4% during the first quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock worth $13,318,000 after buying an additional 483,620 shares during the last quarter. Finally, Seven Fleet Capital Management LP increased its position in Taysha Gene Therapies by 140.4% during the second quarter. Seven Fleet Capital Management LP now owns 1,504,400 shares of the company’s stock worth $9,940,000 after buying an additional 878,692 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $4.49 on Wednesday. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. Taysha Gene Therapies has a 1 year low of $3.69 and a 1 year high of $7.30. The business has a fifty day simple moving average of $5.50 and a 200 day simple moving average of $5.69. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -10.69 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, sell-side analysts predict that Taysha Gene Therapies will post -0.52 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders.